The company highlighted the positive results from its Phase 1 clinical trial of DA-1726, a novel dual agonist targeting obesity and related metabolic disorders. The trial demonstrated robust early weight loss, statistically significant reductions in waist circumference, and improvements in glucose control, all achieved without titration. The results are expected to position DA-1726 as a potential best-in-class treatment in the obesity market.
MetaVia also announced that it has strengthened its balance sheet with gross proceeds of $9.3 million from a public offering in January 2026, which is expected to fund operations into the fourth quarter of 2026. The company has received Institutional Review Board (IRB) approval for its Phase 1 Part 3, 16-week titration studies of DA-1726, with dosing expected to begin in April 2026 and data anticipated in the fourth quarter.
In addition to DA-1726, MetaVia is advancing its pipeline, including vanoglipel, which has shown promising Phase 2a data for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company’s intellectual property portfolio has been bolstered with 39 granted and pending patents for DA-1726 and 48 for vanoglipel, providing protection through at least 2041.
Overall, MetaVia's strategic advancements and financial results reflect a positive outlook for the company as it continues to develop innovative treatments for cardiometabolic diseases.
